Navigation Links
Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
Date:1/29/2013

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although interviewed oncologists in the United States and Europe would like to see a future of personalized medicine targeting different soft tissue sarcoma subtypes, they believe that it is in fact novel chemotherapies that hold the most near-term promise for improving outcomes in this highly fragmented indication.

According to Niche Markets and Rare Diseases: Soft Tissue Sarcoma, the clinical pipeline for the disease is relatively sparse and chemotherapy remains the backbone of current treatment. Additionally, most late-stage research focuses on developing novel chemotherapeutic agents or new formulations of chemotherapy drugs with proven efficacy. There are only a few agents in Phase III clinical trials and the majority are chemotherapeutic agents, while considerably more therapies are in mid-stage development and, depending on data, regulators may be open to considering a filing based only on Phase II results.

Initial clinical trials typically position these agents in refractory populations, where the barrier to gaining regulatory approval is relatively low. However, expansion into first-line populations is underway for a number of novel agents in development. Decision Resources forecasts that four agents will launch for soft tissue sarcoma between now and 2018 – palifosfamide (Ziopharm's Zymaphos), eribulin (Eisai's Halaven), crizotinib (Pfizer's Xalkori) and Threshold Pharmaceuticals' TH-302.

"Although we believe that palifosfamide will gain approval for the treatment of soft tissue sarcoma, it will likely not have a significant impact on overall survival outcomes for patients, being largely equivalent to ifosfamide in this regard, although palifosfamide will demonstrate superior progression-free survival over doxorubicin alone," said Decision Resources Therapy Leader of Oncology Joanne Graham, Ph.D. "The key advantages of palifosfamide will be reduced neurotoxicity and improved ease of administration, especially once the oral capsule is available. It's anticipated that the improved convenience over ifosfamide—namely, reduced hospital stay and alleviation of the need for hydration—will offset the inevitable higher price of palifosfamide and will drive high uptake, especially once it becomes available in Europe."  

About Soft Tissue Sarcoma

Soft Tissue Sarcoma is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
2. Oncologists restrict pharmaceutical sales rep access at accelerating rates
3. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
4. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
7. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
8. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
9. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
11. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):